On March 8, 2022 Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinicalstage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, reported that preclinical data from its VaccibodyTM vaccine platform technology will be presented at the upcoming 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana (Press release, Nykode Therapeutics, MAR 8, 2022, View Source [SID1234609768]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:
Abstract #: 3558
Title: A novel and versatile cytokine empowered DNA vaccine platform with superior immune activating potential Authors: Beraas, et al.
Session Title: Vaccines: Oncolytic and Prophylactic
Session Date and Time: Tuesday, April 12, 2022 | 1:30 p.m. – 5:00 p.m. ET

The abstract is available in the Scientific Papers and Presentations section of the Company’s website. The e-poster will be available on the Company’s website on Friday, April 8, 2022.